Navigation Links
Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
Date:12/18/2009

to have entered into a great partnership with Ambit," stated Masafumi Nogimori, president and chief executive officer of Astellas. "We believe that AC220, as the most selective and advanced FLT3 kinase inhibitor, has the potential to provide a new treatment option for AML where high unmet medical needs exist. Astellas is strongly committed to focus on oncology and this partnership is a significant milestone to establish our franchise in oncology."

"With their strategic commitment to the development and commercialization of innovative oncology products, Astellas is an ideal partner for Ambit," said Scott Salka, Chief Executive Officer of Ambit Biosciences. "This collaboration establishes a comprehensive and global leadership position in the discovery and development of FLT3 kinase inhibitors, and we look forward to working closely with Astellas to explore the clinical utility of AC220 in AML and other indications."

About AC220

AC220, Ambit's lead product candidate, is being developed in collaboration with Astellas Pharma Inc. and is a novel, potent, highly selective, orally bioavailable second-generation FLT3 inhibitor. AC220 is currently under evaluation in a Phase 2 clinical trial designed to support potential registration of AC220 as monotherapy treatment in adult and elderly patients with relapsed/refractory AML that have the internal tandem duplication (ITD) mutation in the FLT3 kinase. AML is one of the most common types of blood cancers in adults, and the FLT3 kinase is mutated and constitutively activated in 25-40 percent of such patients. FLT3 ITD mutations predict poor prognosis and decreased response to existing treatments, including chemotherapy and hematopoietic stem cell transplant. Ambit leveraged KINOMEscan(TM), the company's proprietary, high-throughput method for screening small molecule compounds against a large number of human kinases, to advance AC220 from initial chemistry to clinical candi
'/>"/>

SOURCE Ambit Biosciences Corporation; Astellas Pharma Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference
2. Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting
3. Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
4. CeloNova BioSciences CEO Urges More Heart, More Passion, More Honesty, and All Urgency in Developing Medical Devices
5. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
6. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
7. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
8. Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results
9. Cell Biosciences Completes Acquisition of Alpha Innotech
10. Neurocrine Biosciences Reports Third Quarter 2009 Results
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Dec. 15, 2014 As medical device manufacturers ... Labeling) markup language standard, content teams have a greater ... to work with the standard. Starting January 2015, Data ... webinars on the benefits and the critical aspects of ... be facilitated by Howard Shatz , DCL,s SPL ...
(Date:12/14/2014)... Dec. 14, 2014  ChartSpan, a consumer platform for ... iPhone and iPad medical app in the ... http://photos.prnewswire.com/prnh/20141214/164317 ChartSpan is an iPhone ... request, manage and send electronic healthcare records. The product ... grew tired of waiting for the healthcare system to ...
(Date:12/13/2014)... 12, 2014 Mindray Medical International Limited ("Mindray", ... and marketer of medical devices worldwide, today announced shareholder ... held in Hong Kong on ... shareholders voted to re-elect incumbent directors Li Xiting and ... shareholders did not re-elect Peter Wan as ...
Breaking Medicine Technology:Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 2Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 3ChartSpan Becomes The Most Downloaded Medical App in America 2ChartSpan Becomes The Most Downloaded Medical App in America 3Mindray Announced Shareholder Resolutions Post 2014 Annual General Meeting 2
... and Potentially Suited for Once,Daily Administration, PRINCETON, ... an innovator in the discovery and development ... results,from the initial Phase 1 clinical trial ... for the treatment of hypertension,and diabetic nephropathy. ...
... for potential combination,therapies and details of N3/4A ... April 11, 2007 /PRNewswire-FirstCall/ --,InterMune, Inc. announced ... vitro experiments concerning its HCV protease inhibitor,ITMN-191, ... at the 42nd,Annual Meeting of the European ...
Cached Medicine Technology:Pharmacopeia Announces Positive Results from Initial DARA Clinical,Trial 2Pharmacopeia Announces Positive Results from Initial DARA Clinical,Trial 3Pharmacopeia Announces Positive Results from Initial DARA Clinical,Trial 4Pharmacopeia Announces Positive Results from Initial DARA Clinical,Trial 5InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting 2InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting 3InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting 4
(Date:12/17/2014)... December 17, 2014 Dr. Myo Nwe is ... Loss Diet of the Future” and co-founder of the Ace ... book, Dr. Nwe takes a broad look at the industry ... up under scientific scrutiny. On film and in television shows, ... mostly toward the social aspects and played for basic laughs, ...
(Date:12/17/2014)... A group of 127 scientists sent an ... reaction to a recent statement by the center that was ... derogated the efficacy of all brain exercises. , Signatories to ... of the center’s statement critical of brain exercise companies that ... overstated its case, in a document it had entitled “A ...
(Date:12/17/2014)... Project Veritas is releasing a video ... MIT economist and Obamacare architect Jonathan Gruber to public ... the interview, which is being distributed on YouTube. , ... mislabeling in the Affordable Care Act in order to ... billion dollar per year tax grab. , “President Obama ...
(Date:12/17/2014)... (HealthDay News) -- Poor students get more fruits and vegetables ... finds. But, the opposite is true for students from ... vegetables at school may give a healthy boost to poor ... what the family income level, students all ate a similar ... The study was published recently in the journal ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
Breaking Medicine News(10 mins):Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Poor Students Eat Healthier Foods at School, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3
... Not-for-Profit Company,s Desire to Serve Seniors and ... Markets, LONG BEACH, Calif., July 8 ... investment banking, has been appointed vice,president of mergers ... CEO David Schmidt announced today. With this appointment, ...
... ran,up against her state,s discriminatory child custody law when ... to battle to get her back. To help,parents who, ... and,deserve, to keep or regain custody of their children, ... initiative to,educate legislators around the country in order to ...
... President and CEO Blue Cross and Blue,Shield Association, ... executive officer of the Blue Cross and Blue Shield,Association, ... launch,of a new healthcare coalition, Health Care America Now:, ... strongly with the,Health Care America Now coalition that everyone ...
... Syrup containing sugar substitute xylitol actually helps prevent cavities, ... A new sweet treat that actually prevents children,s cavities ... The tasty syrup, which contains the sugar substitute xylitol, ... a role in protecting permanent teeth, says a ...
... Nashville, Tenn. July 7, 2008 A new article ... and possibly magnesium and calcium by dietary means may ... pressure in people with hypertension. A high intake of these ... coronary heart disease and stroke. These findings are published in ...
... play in preventing, recovering from ... health information theft, CHICAGO, ... theft of their medical identity and follow a,"checklist" of recovery steps ... new practice brief, "Mitigating Medical,Identity Theft," published in the July issue ...
Cached Medicine News:Health News:SCAN Health Plan Appoints Arthur Henkel Vice President of Mergers and Acquisitions 2Health News:Collaborative Launches Initiative to Protect Rights of Parents with Mental Illnesses 2Health News:Collaborative Launches Initiative to Protect Rights of Parents with Mental Illnesses 3Health News:Blue Cross and Blue Shield Association Statement: Health Care America Now 2Health News:A Sweet Way to Shield Baby's Teeth 2Health News:A Sweet Way to Shield Baby's Teeth 3Health News:Leading worldwide cause of cardiovascular disease may be modified by diet 2Health News:Mitigating Medical Identity Theft: AHIMA Journal Provides Patient Tools to Secure Health Information 2Health News:Mitigating Medical Identity Theft: AHIMA Journal Provides Patient Tools to Secure Health Information 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: